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Abstract
Background: PPARδ (NR1C2) promotes lipid accumulation in human macrophages in vitro and
has been implicated in the response of macrophages to vLDL. We have investigated the role of
PPARδ in PMA-stimulated macrophage differentiation.
The THP-1 monocytic cell line which displays macrophage like differentiation in response to
phorbol esters was used as a model system. We manipulated the response to PMA using a potent
synthetic agonist of PPARδ , compound F. THP-1 sub-lines that either over-expressed PPARδ
protein, or expressed PPARδ anti-sense RNA were generated. We then explored the effects of
these genetic modulations on the differentiation process.
Results: The PPARδ agonist, compound F, stimulated differentiation in the presence of sub-
nanomolar concentrations of phorbol ester. Several markers of differentiation were induced by
compound F in a synergistic fashion with phorbol ester, including CD68 and IL8. Over-expression
of PPARδ also sensitised THP-1 cells to phorbol ester and correspondingly, inhibition of PPARδ by
anti-sense RNA completely abolished this response.
Conclusions: These data collectively demonstrate that PPARδ plays a fundamental role in
mediating a subset of cellular effects of phorbol ester and supports observations from mouse
knockout models that PPARδ is involved in macrophage-mediated inflammatory responses.
Background
The peroxisome proliferator activated receptors (PPARs)
function as molecular sensors of dietary fatty acids and
serum lipoproteins, and are central to many cellular and
metabolic processes including development, prolifera-
tion, differentiation and lipid homeostasis. There are
three isoforms of: α, γ and δ, with its own tissue-specific
distribution, suggesting that different functions can be
ascribed to each receptor [1-6].
PPARα plays an important role in lipid homeostasis –
agonists upregulate peroxisomal β-oxidation and thus
clear circulating lipids [2]. It is also a negative regulator of
inflammation, demonstrated by the fact that the PPARα
knockout mouse exhibits a prolonged inflammatory
response [7]. Activation of PPARα also leads to an upreg-
ulation in IκB which prevents nuclear translocation of NF-
κB, and thus leads to the inhibition of NF-κB transactiva-
tion of a number of pro-inflammatory gene products
[8,9].
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well documented [8-11] and there is also evidence impli-
cating this receptor in the development of the human
macrophage [9,12-15]. Both mouse and human athero-
sclerotic lesions show a high level of PPARγ expression
and these findings provoked intense interest in the regula-
tory actions of PPARs in monocyte-macrophage biology.
However, recent studies with PPARγ-null mice and mouse
ES cells indicate that this receptor is neither essential for
nor substantially affects the development of the mouse
macrophage lineage both in vitro and in vivo [12]. Support-
ing the notion that PPARγ acts as positive regulator of ter-
minal differentiation (at least in some cell types) is the
observation that agonists are anti-proliferative [16-20].
The functions of PPARδ are less well characterised,
although studies of the δ-null mouse reveal a develop-
mental role [21], and previous work from this laboratory
has demonstrated a role in lipid metabolism [22]. Activa-
tion of PPARδ in the macrophage leads to lipid accumula-
tion, with an increase in mRNA levels of the scavenger
receptors SR-A and CD36. A downregulation of Cyp27
and ApoE, both genes involved in macrophage lipid
export is also observed. Furthermore, PPARδ appears to
mediate macrophage lipid loading by vLDL [23] and may
be the target of oxidised lipids liberated from oxLDL [24].
In agreement with this the deletion of PPARδ in macro-
phages profoundly decreases atherogenesis in an athero-
sclerosis prone mouse model [25]. Other studies have also
revealed PPARδ to be involved in the proliferation and
differentiation of several cell types: while the expression
and activation of PPARγ is crucial for the terminal differ-
entiation of the adipocyte, δ is involved in the very early
stages of this cascade [26]. It appears that, at the initiation
of adipogenesis, PPARδ is pro-proliferative and its activa-
tion leads to mitotic clonal expansion. Its role in prolifer-
ation is confirmed by its role in intestinal tumorigenesis –
expression is up-regulated in human colorectal cancer
cells and by β-catenin, whilst expression is down-regu-
lated by the tumour suppressor APC [17,26-28]. PPARδ is
also known to be involved in the epidermal wound heal-
ing response [29,30]. Pro-inflammatory cytokines such as
TNF-α increase PPARδ expression as well as triggering pro-
duction of endogenous ligands for this receptor. The
PPARδ knockout mouse is both severely delayed with
respect to inflammatory cytokine-stimulated epidermal
differentiation and more sensitive to TNF-α induced
apoptosis. PPARδ has been described as "defining the cel-
lular response to stress" [29] with the up-regulation of its
expression directing TNF-α signalling away from the
apoptotic pathway and towards cell survival and
differentiation.
We have shown that PPARδ is a positive effector of lipid
accumulation in the macrophage [22] and thus may be
involved in the formation of the macrophage-derived
foam cell. The initiating event in plaque formation is
often considered to be an inflammatory response to
endothelial injury, with dyslipidaemia leading to a suben-
dothelial accumulation of modified LDL. This aggregated
lipid is scavenged by monocytes which have left the circu-
lation to enter the arterial intima and differentiated into
activated macrophages. The resulting lipid accumulation
leads to the formation of the macrophage-derived foam
cell, and such cells perpetuate the disease state by produc-
ing cytokine signals for further monocyte recruitment.
We now present data that implicate PPARδ, not only in
lipid accumulation, but also in macrophage differentia-
tion. We have used, as an in vitro model of macrophage
differentiation, THP-1 cells, a human monocyte-derived
cell line that differentiates in response to phorbol ester.
We have demonstrated previously that PMA-induced dif-
ferentiation is accompanied by a marked upregulation in
expression of PPARδ . It has also been shown that PMA is
an activator of PPARδ and in this study we have demon-
strated that PPARδ activity modulates the differentiation
state of PMA-treated THP-1 cells.
Results
Up-regulation of PPARδ message and protein expression 
accompanies the differentiation of the THP-1 monocyte-
derived macrophage
The THP-1 cell line is widely used as a model for the inves-
tigation of macrophage biology. These are suspension
cells which could be induced to differentiate in the pres-
ence of the protein kinase C activator, phorbol ester
(PMA), after treatment with which they became adherent
to the culture substratum. This process was accompanied
by an up-regulation in the PPARδ mRNA (Fig. 1A) begin-
ning within 2 h of the PMA stimulus and reaching a peak
at 24 h. This elevation in the mRNA was accompanied by
an increase in protein expression (Fig. 1B).
PMA is an activator of PPARδ
In order to investigate the effect of PMA on PPARδ signal-
ling, we employed a transient transfection approach.
COS-1 cells were transfected with a luciferase reporter
plasmid containing 4 copies of the liver fatty acid binding
protein PPRE in front of a minimal TK promoter and a
plasmid directing the expression of full length PPARδ .
The ability of increasing concentrations of PMA to activate
PPARδ was tested in a dose response (Fig. 1C) and the
results indicated that phorbol ester is a very effective acti-
vator of the receptor, achieving a 4–5 fold maximal induc-
tion compared to the vehicle-only control at
approximately 1 nM PMA. This appeared to be due
entirely to activation of PPARδ as no increase in PPARδ
protein was observed upon treatment of the COS-1 cells
with PMA (data not shown). Transient transfectionPage 2 of 10
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Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/9PPARδ expression and activity is increased by phorbol esterFigure 1
PPARδ expression and activity is increased by phorbol ester. A: Time course of induction of PPARδ message in 
response to phorbol ester. THP-1 cells were plated in RPMI medium supplemented with 10% FCS and 1 nM PMA at a density 
of 1 × 106 per well. At each time point, cells were lyzed and RNA prepared, followed by cDNA synthesis. QPCR analysis was 
performed using PPARδ-specific primers and probe to determine the amount of message. Results are expressed as total rela-
tive to 18S and were performed in triplicate. B: Expression of PPARδ protein by THP-1 cells is up-regulated in response to 
phorbol ester. THP-1 cells were plated in RPMI medium supplemented with 10% FCS and either 1 nM PMA or vehicle and 
incubated for 48 h. Cells were then lyzed directly into SDS-PAGE sample buffer for Western blotting. Blots were probed using 
a rabbit polyclonal anti-serum raised against a GST-PPARδ AB domain fusion protein. C: COS-1 cells were transiently co-
transfected with pFABPLuc and pCLDNhPPARδ. Transfection efficiency was controlled for by co-transfection with a plasmid 
encoding β-galactosidase. Cells thus transfected were treated with increasing concentrations of PMA for 24 h after which luci-
ferase activity was measured. D: PMA-induced δ-activation is mediated through the ligand binding domain. COS-1 cells were 
transfected with an expression vector encoding a Gal-4/PPARδ ligand-binding domain chimera. Cells were then treated for 24 
h with compound F, PMA or vehicle only and luciferase readings obtained.Page 3 of 10
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the Gal4 DNA-binding domain is fused in frame to the lig-
and binding domain of PPARδ demonstrated activation
by PMA. Thus, activation of the UAS reporter construct
therefore reflects PMA signalling mediated by the ligand-
binding domain of PPARδ . This is in agreement with the
results of Tan et al. [29]
A PPARδ agonist sensitizes THP-1 cells to PMA
As PMA appears to modulate both expression and activity
of PPARδ, we investigated the dynamics of the THP-1
response to phorbol ester and the PPARδ agonist, com-
pound F. (Fig. 2). PMA induced THP-1 cells to differenti-
ate in a dose-dependent manner, with an EC50 of
approximately 3 nM. Co-treatment of the cells with 100
nM compound F resulted in a reduced EC50 of 1 nM PMA
(Fig. 2A). If THP-1 cells were treated with low levels of
PMA (>1 nM), very few were seen to differentiate, unless
simultaneously treated with compound F, when the
number of cells undergoing differentiation and adhering
to the culture substratum was seen to increase signifi-
cantly (p < 0.0001) in a compound F dose-dependent
manner (Fig. 2B), with maximal activity at approximately
10 nM. PMA-induced differentiation was dependent on
continued PMA signalling: when cells were treated with a
single dose of PMA (1 nM), and the PMA was subse-
quently withdrawn 48 h later, the cells began to de-differ-
entiate and detach from the substratum. After 8 days, less
than 20% of the initial total remained adherent. When the
cells were exposed to 20 nM compound F treatment fol-
lowing the PMA withdrawal, the differentiated phenotype
was retained for significantly longer (p < 0.0001), with
some 50% of cells still attached (Fig. 2C). These results
indicate that PPARδ activity is required for both the initi-
ation and maintenance of adhesion. However, despite the
fact that compound F treated THP-1 cells showed acute
sensitivity to very low doses of PMA, compound F alone
was not sufficient to induce differentiation indicating that
other factors in addition to expression and ligand activa-
tion of PPARδ are involved in the induction of macro-
phage differentiation.
Differentiation markers are regulated by compound F and 
PMA in a synergistic manner
Cells were treated with increasing doses of PMA for up to
48 h with medium containing 0.5% FCS, in the presence
(broken line) or absence (solid line) of compound F. Cells
were lyzed and cDNA prepared for QPCR analysis. Several
gene targets were analyzed for their known role in macro-
phage differentiation. CD68 (Fig. 3A) is a classical marker
of macrophage differentiation. In the absence of com-
pound F there was a slight increase in CD68 mRNA with
increasing concentrations of PMA. In the presence of 20
nM compound F, there was a profound increase in mes-
sage in response to PMA treatment. Similar effects were
Phorbol ester and compound F co-operate to induce and maintain differe tiation of THP-1 cellsFigure 2
Phorbol ester and compound F co-operate to induce 
and maintain differentiation of THP-1 cells. A: Com-
pound F sensitizes THP-1 cells to PMA-induced adherence. 
Dose-responses of THP-1 cells to PMA were prepared in the 
presence of vehicle alone (squares) or 100 nM compound 
F(triangles). Cells were plated in RPMI medium (0.1% FCS) 
and harvested after 48 h. Cell numbers were determined by 
fluorimetric analysis of SYBR green stained plates. B: Com-
pound F co-operates with phorbol ester in promoting differ-
entiation of THP-1 cells. Cells were plated for 48 h in RPMI 
medium supplemented with 0.1% FCS and 0.5 nM PMA and a 
compound F dose-response performed. Results obtained 
were subjected to non-linear regression analysis. C: Com-
pound F maintains the adherence of THP-1 cells in the 
absence of a prolonged PMA stimulus. THP-1 cells were 
plated in RPMI supplemented with 10% FCS and 1 nM PMA. 
After 48 h, the PMA was removed and replaced with either 
100 nM compound F (triangles) or vehicle only (squares). At 
48 h intervals up to 6 days, the number of cells remaining 
adherent to the culture substratum was measured by fluori-
metric analysis of SYBR green stained plates and the results 
compared to a standard curve.Page 4 of 10
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oattractant, known to be important in the development of
the inflammatory phenotype. Adipophilin (Fig. 3C) and
adipocyte fatty acid binding protein (AFABP) (Fig. 3D)
both showed a similar synergistic response following
treatment with PMA and compound F. Both of these are
crucial to lipid trafficking and storage during the differen-
tiation of macrophages into a foam cells and we and
others have shown previously that they are targets of
PPARδ [22,23]. Levels of IL1β were not significantly
affected (Fig. 3E).
MMP9 (Fig. 3F) is a matrix metalloproteinase important
in inflammation. MMP9 facilitates the entry of macro-
phages into peripheral tissues by allowing them to pene-
trate the basement membrane underlying the
endothelium. Osteopontin (Fig. 3G) is another macro-
phage differentiation marker. Both of these gene targets
showed an up-regulation in message in response to PMA,
and this effect was still present in the cells treated with the
compound F. In this case, the effect of the PPARδ agonist
was to blunt the PMA response.
Over-expression of PPARδ is functionally similar to 
treating cells with compound F
Stable cell lines over-expressing PPARδ were generated as
previously described [22]. The effect of this on the PMA-
induced differentiation response is shown in Fig. 4A. The
PPARδ over-expressing cells differentiated at much lower
concentrations of PMA when compared to the parental
THP-1 cells. This effect was even greater than that
observed with compound F. Over-expression of PPARδ
was also able to limit the de-differentiation in the absence
of a prolonged PMA stimulus in a manner similar to com-
pound F treated parental cells (p < 0.0001, Fig. 4B).
PPARδ is required for the differentiation of THP-1 
monocyte-derived macrophages
Stable cell lines were also generated that expressed PPARδ
anti-sense mRNA. These cell lines also appeared to be nor-
mal with respect to their routine culture characteristics.
Fig. 5A shows western blotting of parental, SENSE and
ANTISENSE cell lines, both in the presence and absence of
PMA. PPARδ expression is undetectable unless the cells
are treated with PMA, while untreated SENSE cells show a
level of expression similar to that observed with the PMA-
treated parental cells. ANTISENSE cells do not express
PPARδ even when stimulated with PMA. Figs. 5B and 5C
show the response of the cell lines to treatment with 8 nM
Compound F modulates phorbol ester activation of gene targets involved in differentiationFigure 3
Compound F modulates phorbol ester activation of gene targets involved in differentiation. Cells were plated in 
RPMI 1640 supplemented with 0.5% FCS. A PMA dose-response was carried out, in the presence of either vehicle alone 
(squares, broken lines) or compound F (triangles, solid lines). Cells were lyzed after 24 h (CD68; A, IL8; B, AFABP; C and adi-
pophilin; D) or 48 h (IL1β ; E, Osteopontin; F and MMP-9; G). RNA was prepared from cell lysates and cDNA was prepared 
for QPCR analysis.Page 5 of 10
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density of 5 × 105/ml and left for 48 h, during which time
all three cell lines underwent a doubling in number. At 48
h, the cells were treated with a single dose of PMA. This
was left on the cells for a further 48 h, after which the
medium was removed and replaced with medium with-
out PMA. The cells were left for a further 96 h. Following
Over-expression of PPARδ potentiates the differentiation responseFigur  4
Over-expression of PPARδ potentiates the differenti-
ation response. A: Both wild type (squares) and SENSE 
cells (inverted triangles) were treated with increasing con-
centrations of PMA. Numbers of adherent cells were quanti-
fied by SYBR green staining and compared to a standard 
curve. B: Over-expression of PPARδ (inverted triangles) 
enhances the maintenance of adhesion following a single 
treatment with PMA when compared with the parental cell 
line (squares). For comparison, the compound F result (trian-
gles; broken line) is also shown.
PPARδ is necessary for PMA stimulated adherence of THP-1 cellsFigure 5
PPARδ is necessary for PMA stimulated adherence of 
THP-1 cells. Wild-type THP-1 cells (squares), SENSE 
(inverted triangles) and ANTISENSE cells (circles) were 
plated at a density of 5 × 105 cells/ml. After 48 h the cells 
were treated with PMA and this was maintained for a further 
48 h. After this time the PMA was removed. At all stages, 
both adherent (A) and non-adherent cells (B) were counted 
with SYBR green and cell number calculated from a standard 
curve.Page 6 of 10
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ent (Fig. 5C) cell number was determined by SYBR stain-
ing at 48 h intervals. Fig. 5C shows that no ANTISENSE
cells ever became adherent following PMA treatment,
indicating that PPARδ is required for the differentiation of
THP-1 cells. When the non-adherent cells are considered
(Fig. 5B) it can be seen that, for the duration of the PMA
treatment, ANTISENSE cells did not proliferate. Once the
PMA was removed, the cells rapidly resumed prolifera-
tion, indicating that PMA-induced growth arrest of THP-1
cells is PPARδ-independent.
Discussion
Macrophages have a central role as effector cells at sites of
chronic inflammation, such as the atherosclerotic plaque,
and the differentiation of a monocyte into a macrophage
represents a key event in this process; underlying mecha-
nisms may therefore present attractive targets for thera-
peutic intervention. Work by the group of Wahli [29] has
suggested a model for keratinocyte differentiation
whereby PMA-induced activation of PKC leads to PLA2-
induced liberation of arachidonic acid and subsequent
generation of endogenous ligands for PPARδ. Activation
of PPARδ leads to modulation of gene targets involved in
the differentiated keratinocyte phenotype. This study has
examined the hypothesis that PMA signalling in macro-
phage differentiation involves PPARδ. In this THP-1
model, differentiation is induced by treatment of the cells
with the potent inflammatory stimulus, phorbol ester
(PMA). Following treatment with PMA, we observed that
PPARδ message began to rise almost immediately and this
was reflected in the level of protein expression observed at
48 h. PMA represents a potent and pleiotropic inflamma-
tory insult to the cell, and parallels can be drawn with the
response to skin wounding (or treatment with PMA) dem-
onstrated by Wahli et al [29,30]. In normal adult skin,
PPARδ expression is undetectable, but this is upregulated
in response to injury. Treatment with PPARδ agonists
induces the expression of keratinocyte markers of differ-
entiation. This up-regulation of PPARδ is associated with
necrosis and it appears that it is this receptor, which medi-
ates the necrosis-associated signals that ultimately trigger
keratinocyte differentiation. It has also been shown that,
in skin, PMA-induced differentiation is PPARδ-depend-
ent: the peak of PPARδ expression coincides with a switch
to cell cycle arrest and the onset of differentiation.
Differentiation and proliferation can be considered func-
tional inverses of one another: commitment to differenti-
ation invariably involves the cell entering a state of growth
arrest. Differentiation of the macrophage has several dis-
tinct phases. Initially the cell will become growth arrested,
then it will become activated and attach to the substratum
(whether it be the culture vessel or the endothelium) and
finally it must maintain its differentiated phenotype. We
have shown that PMA was able to induce growth arrest of
THP-1 cells and promote adhesion in a dose-dependent
manner (EC50 = 3 nM). This effect was potentiated by the
highly specific PPARδ agonist, compound F, which
reduced the EC50 to 1 nM. Here parallels can be drawn
with the adipocyte differentiation cascade: adipocyte
differentiation can be induced if the pre-adipocytes are
treated by PPARγ agonists, but this effect is dependent on
the presence of signalling by insulin [31].
It is apparent that PPARδ is involved not only in the initi-
ation of THP-1 differentiation, but also in its mainte-
nance. PMA-induced molecular events appear, generally,
to be short-lived: its effects with respect to differentiation
are reversible by its removal. The activation of PPARδ
appears to stabilise the PMA response, maintaining the
differentiated phenotype even in the absence of pro-
longed PMA stimulation. Therefore, PPARδ activation
may represent a transition from acute effects of PMA to
longer-term genomic signalling.
In keratinocytes, both PMA and TNF-α have been shown
to elicit differentiation and inflammation via PPARδ [29].
Both stimuli induce PPARδ expression via activation of
AP-1 sites in the promoter. This work and that of others
[29] has shown that PMA can activate a Gal4PPARδ LBD
fusion protein, suggesting the generation of endogenous
ligands. However, the identity of a PMA inducible-endog-
enous ligand has yet to be elucidated.
In keeping with the notion that the effects of phorbol ester
on differentiation are mediated through PPARδ, we have
demonstrated that PPARδ-specific genes are also targets of
PMA, and that the two compounds synergise in regulating
expression of genes known to be characteristic of the dif-
ferentiated phenotype. IL8 is of particular interest because
of its role in inflammation and atherosclerosis [32]. Other
PPARδ-specific targets, such as adipophilin and AFABP are
associated with the differentiation of macrophages into
foam cells [22], important in the development of athero-
sclerosis, another chronic inflammatory condition which
can be regarded as a pathological differentiation. That
PPARδ is involved in chronic inflammation is perhaps not
surprising: this isoform is capable of acting as an intrinsic
transcriptional repressor of the other isoforms, PPAR-α
and -γ, and it has been suggested that this may account for
its ubiquitous expression, acting as a tissue-specific regu-
lator of PPAR target genes [33]. It is known that both
PPARα and γ are involved in the limitation of the inflam-
matory response [7], and it may be that up-regulation of
expression of PPARδ allows α- and γ-mediated anti-
inflammatory signalling to be overcome, permitting the
inflammatory response to continue unchecked. Indeed,
PPARγ signalling has been specifically implicated in the
resolution of inflammation [34].Page 7 of 10
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approach, demonstrating gain- and loss-of-function to
implicate PPARδ in macrophage differentiation. Our data
is supported by the fact that leukocytes from PPARδ-null
mice have an 80% reduction in Mac-1 expression [23] and
that PPARδ-null derived bone marrow supports very lim-
ited atherogenesis [25]. Our study extends these observa-
tions to a human system, and confirms that targeting of
the PPARδ signalling pathway may have therapeutic ben-
efits in conditions such as rheumatoid arthritis and
atherosclerosis.
Methods
Materials
RPMI 1640, DMEM, fetal bovine serum (FBS) and Super-
Script II were purchased from Gibco Life Technologies,
UK. Phorbol-12-myristate-13-acetate (PMA) and G418
were obtained from Sigma-Aldrich, UK and the PPARδ lig-
and 3-propyl-4-(3-(3-trifluoromethyl-7-propyl-6-benz-
[35]-isoxazoloxy)-propylthio)phenylacetic acid (com-
pound F) were a gift from GlaxoSmithKline, UK.
Culture and differentiation of THP-1 cells
The human THP-1 cell line was obtained from ATCC and
grown in RPMI 1640 supplemented with 10% heat-inac-
tivated FBS and 20 µM β-mercaptoethanol. Cells were
maintained at 37°C and 5% CO2. Experiments were per-
formed in 6-well plates where differentiation was induced
by resuspending the cells in RPMI containing either 0.5%
FBS and PMA as described in the figure legends. Experi-
ments were performed in both the presence, or absence of
compound F (either 20 or 100 nM final concentration).
All drugs were added with DMSO as a vehicle and were
replaced at intervals of 48 hours unless otherwise stated.
Cell counting
At the end of each experiment, adherent THP-1 cells were
fixed with a solution of 4% paraformaldehyde, 1% Triton-
X for 30 minutes at room temperature, following which
the DNA was stained with a 1: 10,000 SYBR green solution
(Molecular Probes). Plates were incubated for 24 h at 4°C
in the dark. Cells were washed in PBS and the relative
numbers determined from a standard curve by fluorime-
try using a LabSystems FluoroSkan Ascent FL microplate
reader.
Isolation of stable cell lines
PPARδ over-expressing cell lines (SENSE) and THP-1 anti-
sense cells (ANTISENSE) were prepared as described pre-
viously [22]. Briefly, THP-1 cells were transfected with an
expression vector containing the entire human PPARδ
coding sequence in either sense or anti-sense orientation
respectively. Transfection was by a modified DEAE-dex-
tran procedure [36] and pools of stable cells were selected
by maintaining cells in medium containing 1 mg/ml
G418, 10% FBS and 10% THP-1 conditioned medium,
Table 1: Sequences of primers and probes used for QPCR in Fig. 3.
Target Sequence (5'-3')
PPARδ Forward: GGGACCACAGCATGCACTTC
Reverse: TGCAGTTGGTCCAGCAGTGA
Probe: CCAGCAGCTACACAGACCTCTCCCGG
CD68 Forward: TCCTCGCCCTGGTGCTTA
Reverse: GGGCCTGGTAGGCGGAT
Probe: TTTCTGCATCATCCGGAGACG
IL8 Forward: AAGGAACCATCTCACTGTGTGTAAAC
Reverse: ATCAGGAAGGCTGCCAAGAG
Probe: TGACTTCCAGCTGGCCGTGGC
AFABP Forward: AGTAGGAGTGGGCTTTGCCA
Reverse: TCACATCCCCATTCACACTGA
Probe: AGGAAAGTGGCCGTGGC
Adipophilin Forward: TGGCAGAGAACGGTGTGAAG
Reverse: CTGGATGATGGGCAGAGCA
Probe: CATCACCTCCGTGGCCATGACCA
IL1β Forward: TGAGCACCTTCTTTCCCTTCA
Reverse: GTACAGGTGCATCGTGCACAT
Probe: CCTATCTTCTTCGACACATGGGATAACGAGGC
Osteopontin Forward: TGACCCATCTCAGAAGCAGAATC
Reverse: CTCTTGTTTAAAGTCATTGGTTTCTTCA
Probe: CCTAGCCCCACAGAATGCTGTGTCCTC
MMP9 Forward: GCTCACCTTCACTCGCGTG
Reverse: CGCGACACCAAACTGGATG
Probe: ACAGCCGGGACGCAGACATCGPage 8 of 10
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dure was repeated until cell killing stopped and robust
growth was observed. Six pools from independent trans-
fections were obtained, each pool displayed a similar
phenotype.
Plasmids and transient transfection procedures
COS-1 cells were transfected in 6-well plates using DEAE-
dextran as described previously [37]. The reporter con-
struct used was pFABPLuc, which consists of four copies of
the human peroxisome proliferator response element
from the human liver fatty acid binding protein (FABP)
gene in front of the herpes simplex virus thymidine kinase
promoter, cloned immediately upstream of the cDNA
encoding firefly luciferase in pGLBAS (Promega). The
PPARδ expression vector (pCLDNhPPARδ) contained the
coding sequence for human PPARδ under the control of
the enhancer/promoter of the human cytomegalovirus.
The Gal4/LBD plasmid consisted of an in-frame fusion of
the Gal4 DNA-binding domain and the ligand-binding
domain of PPARδ . The reporter plasmid without the
PPRE (TKLuc) and the empty expression vector (pCLDN)
were used as controls. pSV β-galactosidase (Promega) was
co-transfected in all cases in order to control for transfec-
tion efficiency. Following transfection and recovery, the
cells were incubated for 18 h with DMEM containing 10%
FBS and 1% streptomycin/penicillin, supplemented with
vehicle (DMSO), compound F or PMA. Cells were ana-
lysed for β-galactosidase and luciferase activities using
assay kits as described by the manufacturer (Promega).
Data are presented as the ratio of relative light units
obtained with the luciferase assay to the absorbance
obtained at 415 nm in the β-galactosidase assays (relative
luciferase).
Western Blotting
THP-1 wild type, SENSE and ANTISENSE cells were
treated with PMA or vehicle for 48 h following which they
were lyzed in SDS-PAGE loading buffer and analysed
using standard Western blotting procedures. The primary
antibody was either PPARδ antiserum (a gift from Dr
David Bell), used at a 1:2000 dilution, or an antibody
raised against the AB domain (residues 1–100) of PPARδ,
used at a dilution of 1:500. The AFAR antiserum
(obtained from Prof. John Hayes) was used at a 1:3000
dilution. The secondary detection reagent, a peroxidase
conjugated mouse anti-rabbit IgG antiserum (Sigma) was
used at a dilution of 1:3000. Bands were visualised using
enhanced chemiluminesence (ECL+) as described by the
manufacturer (Amersham Pharmacia Biotech).
RNA extraction and analysis
RNA was extracted from differentiated and undifferenti-
ated THP-1 cells using the Qiagen RNeasy kit. cDNA was
synthesised from this RNA using SuperScript II. QPCR
analysis was performed on triplicate experiments using
the standard Applied Biosystems procedures, with primers
and probes described in Table 1. 18S RNA was quantified
using an assay from Applied Biosystems.
Statistical analysis
All graphs and statistics were prepared using Graphpad
Prism for the Macintosh v3.0 (Graphpad Inc., San Diego,
CA). p values were calculated using two-way ANOVA,
unless otherwise stated.
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